Other molecular markers, such as alpha‐thalassemia mental retardation X‐linked (ATRX), telomerase reverse transcriptase (TERT), EGFR, tumor protein 53(TP53), cyclin‐dependent kinase inhibitor 2A/B (CDKN2A/B), proto‐oncogene B‐Raf and v‐Raf murine sarcoma viral oncogene homlog B (BRAF), cyclin D1 (CCND1), and cyclin‐dependent kinases 6 (CDK6), have also emerged as crucial factors in glioma classification, prognosis, and targeted therapy121, 122 and have become focal points for radiogenomic investigations.33, 34, 36, 41, 44, 46, 123, 124, 125, 126, 127. This evidence concerns the gene BRAF and glioma.